Pay Now or Pay Later? Don't Ignore Importance of Phase II
By Jennifer Boggs
Wednesday, June 29, 2011
WASHINGTON For drug development firms trying to save money or playing catch-up in a highly competitive field, it might seem a good idea to skimp on Phase II testing by enrolling fewer patients, conducting only one midstage study or even leapfrogging straight to Phase III and hoping that the efficacy signal observed in Phase I wasn't just a fluke.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.